HPLC of Formula: 31938-07-5In 2017 ,《Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity》 appeared in European Journal of Medicinal Chemistry. The author of the article were Liu, Yang; Yin, Yanzhen; Zhang, Zhen; Li, Carrie J.; Zhang, Hui; Zhang, Daoguang; Jiang, Changying; Nomie, Krystle; Zhang, Liang; Wang, Michael L.; Zhao, Guisen. The article conveys some information:
Targeting of Akt has been validated as a well rationalized approach to cancer treatment, and represents a promising therapeutic strategy for aggressive hematol. malignancies. We describe herein an exploration of novel Akt inhibitors for cancer therapy through structural optimization of previously described 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives Our studies yielded a novel series of pyrrolopyrimidine based phenylpiperidine carboxamides capable of potent inhibition of Akt1. Notably, I exhibited robust antiproliferative effects in both mantle cell lymphoma cell lines and primary patient tumor cells. Low micromolar doses of 10h induced cell apoptosis and cell cycle arrest in G2/M phase, and significantly downregulated the phosphorylation of Akt downstream effectors GSK3β and S6 in Jeko-1 cells.2-(3-Bromophenyl)acetonitrile(cas: 31938-07-5HPLC of Formula: 31938-07-5) was used in this study.
2-(3-Bromophenyl)acetonitrile(cas: 31938-07-5) has been used in the synthesis of a series of aminoethylbiphenyls, novel 5-HT7 receptor ligands or 2-(1-cyano-1-(3-bromophenyl))methylidene-3-phenylthiazolidine-4,5-dione.HPLC of Formula: 31938-07-5
Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts